1. THU0188 Evaluation of Single-dose and Steady-State Pharmacokinetics, Bioavailability and Tolerability of the Modified Release Formulation of Tofacitinib vs the Immediate Release Formulation of Tofacitinib in Healthy Volunteers. (9th June 2015) Authors: Lamba, M.; Wang, R.; Fletcher, T.; Alvey, C.; Kushner, J.; Stock, T. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment. (15th July 2016) Authors: van Vollenhoven, R.; Choy, E.; Lee, E.B.; Hazra, A.; Anisfeld, A.; Lazariciu, I.; Biswas, P.; Lamba, M.; Menon, S.; Hodge, J.; Clark, J.D.; Wang, L.; Krishnaswami, S. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 258 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0879 Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Paediatric Patients from Two To Less than Eighteen Years of Age with Juvenile Idiopathic Arthritis. (15th July 2016) Authors: Ruperto, N.; Brunner, H.I.; Hazra, A.; Wang, R.; Mebus, C.; Alvey, C.; Lamba, M.; Krishnaswami, S.; Conte, U.; Wang, M.; Tzaribachev, N.; Foeldvari, I.; Horneff, G.; Kingsbury, D.; Koskova, E.; Smolewska, E.; Vehe, R.K.; Zuber, Z.; Martini, A.; Lovell, D. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1202 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib. (9th June 2015) Authors: van Vollenhoven, R.F.; Tanaka, Y.; Lamba, M.; Collinge, M.; Hendrikx, T.; Hirose, T.; Toyoizumi, S.; Hazra, A.; Krishnaswami, S. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 258 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. THU0143 Pharmacokinetics, Bioavailability and Safety of A Modified Release Once Daily Formulation of Tofacitinib in Healthy Volunteers. (10th June 2014) Authors: Lamba, M.; Wang, R.; Fletcher, T.; Alvey, C.; Hazra, A.; Kushner, J.; Larmann, J.; Stock, T. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. THU0192 Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis. (15th July 2016) Authors: Lamba, M.; Furst, D.; Dikranian, A.; Dowty, M.; Hutmacher, M.; Conrado, D.; Stock, T.; Nduaka, C.; Krishnaswami, S. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 255 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0252 Relationship between Lymphocyte Count and Risk of Infection in Rheumatoid Arthritis Patients Treated with Tofacitinib. (23rd January 2014) Authors: van Vollenhoven, R.; Riese, R.; Krishnaswami, S.; Kawabata, T.; Fosser, C.; Rottinghaus, S.; Lamba, M.; Zwillich, S. H.; Bradley, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. AB0474 Changes in T and B Lymphocyte Subsets with Tofacitinib do not Translate from Nonclinical Species to Humans. (10th June 2014) Authors: Ball, D.J.; Kawabata, T.T.; Vogel, W.M.; Riese, R.J.; Krishnaswami, S.; Lamba, M.; Brown, M.J.; Zwillich, S.H. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 964 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Severe rhabdomyolysis and celiac disease. (8th October 2015) Authors: Mandato, C.; Rossi, A.; Lamba, M.; Caldore, M.; Siani, P.; Vajro, P. Journal: Digestive and liver disease Issue: Volume 47(2015)Supplement 4 Page Start: e272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. (8th July 2013) Authors: Ports, W.C.; Khan, S.; Lan, S.; Lamba, M.; Bolduc, C.; Bissonnette, R.; Papp, K. Journal: British journal of dermatology Issue: Volume 169:Number 1(2013:Jul.) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗